These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 27353264)
1. Eravacycline Pharmacokinetics and Challenges in Defining Humanized Exposure In Vivo. Thabit AK; Monogue ML; Nicolau DP Antimicrob Agents Chemother; 2016 Aug; 60(8):5072-5. PubMed ID: 27353264 [TBL] [Abstract][Full Text] [Related]
2. Zhao M; Lepak AJ; Marchillo K; VanHecker J; Andes DR Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416552 [TBL] [Abstract][Full Text] [Related]
3. Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. Zhanel GG; Cheung D; Adam H; Zelenitsky S; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty A; Gin AS; Hoban DJ; Karlowsky JA Drugs; 2016 Apr; 76(5):567-88. PubMed ID: 26863149 [TBL] [Abstract][Full Text] [Related]
4. Eravacycline (TP-434) is efficacious in animal models of infection. Grossman TH; Murphy TM; Slee AM; Lofland D; Sutcliffe JA Antimicrob Agents Chemother; 2015 May; 59(5):2567-71. PubMed ID: 25691636 [TBL] [Abstract][Full Text] [Related]
5. Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis. Thabit AK; Monogue ML; Newman JV; Nicolau DP Int J Antimicrob Agents; 2018 May; 51(5):727-732. PubMed ID: 29325762 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits. Petraitis V; Petraitiene R; Maung BBW; Khan F; Alisauskaite I; Olesky M; Newman J; Mutlib A; Niu X; Satlin M; Singh RS; Derendorf H; Walsh TJ Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941646 [TBL] [Abstract][Full Text] [Related]
8. Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline. Newman JV; Zhou J; Izmailyan S; Tsai L Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150464 [TBL] [Abstract][Full Text] [Related]
9. Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics. Rodvold KA; Burgos RM; Tan X; Pai MP Clin Pharmacokinet; 2020 Apr; 59(4):409-425. PubMed ID: 31773505 [TBL] [Abstract][Full Text] [Related]
10. Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy Subjects. Newman JV; Zhou J; Izmailyan S; Tsai L Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559132 [TBL] [Abstract][Full Text] [Related]
12. In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus. Lepak AJ; Seiler P; Surivet JP; Ritz D; Kohl C; Andes DR Antimicrob Agents Chemother; 2016 Jun; 60(6):3626-32. PubMed ID: 27044547 [TBL] [Abstract][Full Text] [Related]
13. Eravacycline for the treatment of patients with bacterial infections. Thakare R; Dasgupta A; Chopra S Drugs Today (Barc); 2018 Apr; 54(4):245-254. PubMed ID: 29869646 [TBL] [Abstract][Full Text] [Related]
14. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Connors KP; Housman ST; Pope JS; Russomanno J; Salerno E; Shore E; Redican S; Nicolau DP Antimicrob Agents Chemother; 2014; 58(4):2113-8. PubMed ID: 24468780 [TBL] [Abstract][Full Text] [Related]
15. In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model. Lepak AJ; Marchillo K; Craig WA; Andes DR Antimicrob Agents Chemother; 2015 Feb; 59(2):1258-64. PubMed ID: 25512404 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline. Rodvold KA; Pai MP Clin Infect Dis; 2019 Aug; 69(Suppl 1):S16-S22. PubMed ID: 31367744 [TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Louie A; Kaw P; Liu W; Jumbe N; Miller MH; Drusano GL Antimicrob Agents Chemother; 2001 Mar; 45(3):845-51. PubMed ID: 11181370 [TBL] [Abstract][Full Text] [Related]
18. Determination of the pharmacodynamic profile of daptomycin against Streptococcus pneumoniae isolates with varying susceptibility to penicillin in a murine thigh infection model. Dandekar PK; Tessier PR; Williams P; Zhang C; Nightingale CH; Nicolau DP Chemotherapy; 2004 Apr; 50(1):11-6. PubMed ID: 15084799 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic evaluation of the atypical tetracyclines chelocardin and amidochelocardin in murine infection models. Rox K; Jansen R; Lukežič T; Greweling-Pils M; Herrmann J; Miethke M; Hüttel S; Hennessen F; Abou Fayad A; Holzhausen C; Lundberg CV; Teague J; Sudarman E; Bülter L; Hesterkamp T; Stadler M; Brönstrup M; Müller R Microbiol Spectr; 2024 Jan; 12(1):e0128923. PubMed ID: 38047701 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection. Xiao XM; Xiao YH Acta Pharmacol Sin; 2008 Oct; 29(10):1253-60. PubMed ID: 18817632 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]